Adiponectin in Patients With Metabolic Disorders
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: liver
- Who it enrolls
- age 40 Years to 65 Years; no BMI minimum stated; conditions: Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM)
- Interventions
- SGLT2 inhibitor; GLP-1 RA
- Conditions
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD); Type 2 Diabetes Mellitus (T2DM)
- Phase and size
- NA · 130 participants
- Dates
- Start 2022-03-01
Primary completion 2024-04-08 - Sponsor
- Moscow Regional Research and Clinical Institute (MONIKI) (Other gov)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Change in serum HMW-adiponectin levelsBaseline and 6 months
02Eligibility
Who can take part
Inclusion Criteria: * Written informed consent of the patient to participate in the study * Glycated hemoglobin level exceeding the target by no more than 1%. * Age 40 to 65 years inclusive * Verified diagnosis of MAFLD, according to the criteria of EASL 2020, * Confirmed diagnosis of type 2 diabetes mellitus * Body mass index (BMI) 25-39.9 kg/m2 * Refusal to take any dietary supplements Non-inclusion criteria: * Chronic alcohol abuse (alcoholic fatty liver disease) * Insulin-dependent diabetes * Use of hepatoprotective agents * High risk of atherosclerotic cardiovascular disease (age \> 55 years with coronary, carotid, or lower extremity artery stenosis, or left ventricular hypertrophy) * Chronic kidney disease * Chronic heart failure Exclusion Criteria: * Patient withdrawal of consent * Pregnancy (if applicable) * Decompensation of diabetes during therapy * Development of adverse events associated with therapy.
03Change log
Registry changes
No changes recorded since the trial was added.